// App-Quantinova.ai

: Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.

Researchers

Presenter

  • John L. Gore

Principal Investigators

  • Darlene Dai

  • Robert Benjamin Den

  • Kasra Yousefi

  • Tiffany Le

  • Marguerite Du Plessis

  • Roanna Padre

  • Worlanyo Sosu-Sedzorme

  • Elai Davicioni

  • Paul L. Nguyen

  • Ashley Ross

Medical Centers

  • University of Washington School of Medicine, Seattle, WA

  • GenomeDx Biosciences Inc., Vancouver, BC, Canada

  • Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA

  • GenomeDx Biosciences Inc., San Diego, CA

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Johns Hopkins Medicine, Baltimore, MD

Locations

  • United States

  • Canada

Companies

  • GenomeDx Biosciences

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved